Document is current
Any future updates will be listed below
-
Authors
Garcia-Argibay, Miguel https://orcid.org/0000-0002-4811-2330
Wootton, Robyn E. https://orcid.org/0000-0003-3961-3202
Larsson, Henrik https://orcid.org/0000-0002-6851-3297
Mattheisen, Manuel https://orcid.org/0000-0002-8442-493X
Polimanti, Renato https://orcid.org/0000-0003-0745-6046
Meier, Sandra
- License Information
-
More Information
Article History
Received: 23 April 2025
Revised: 8 January 2026
Accepted: 30 January 2026
First Online: 11 February 2026
Competing interests
: Dr. Henrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; all outside the submitted work. Henrik Larsson is editor-in-chief of JCPP Advances. Dr. Renato Polimanti reports receiving personal fees from Karger Publishers and a grant from Alkermes outside the submitted work. All other authors report no biomedical financial interests or potential conflicts of interest.
